Original language | English (US) |
---|---|
Pages (from-to) | 837-849 |
Number of pages | 13 |
Journal | Journal of Thoracic and Cardiovascular Surgery |
Volume | 147 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2014 |
Externally published | Yes |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pulmonary and Respiratory Medicine
- Surgery
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Thoracic and Cardiovascular Surgery, Vol. 147, No. 3, 03.2014, p. 837-849.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Transcatheter therapies for mitral regurgitation
T2 - A professional society overview from the American College of Cardiology, the American Association for Thoracic Surgery, Society for Cardiovascular Angiography and Interventions Foundation, and the Society of Thoracic Surgeons
AU - O'Gara, Patrick T.
AU - Calhoon, John H.
AU - Moon, Marc R.
AU - Tommaso, Carl L.
N1 - Funding Information: Appendix 1 Author relationships with industry and other entities (relevant)—transcatheter therapies for mitral regurgitation: A professional society overview from the ACC, AATS, SCAI, and STS Committee member Employment Consultant Speaker’s bureau Ownership/ partnership/principal Personal research Institutional, organizational, or other financial benefit Expert witness Patrick T. O’Gara, Co-Chair Brigham and Women’s Hospital—Professor of Medicine; Harvard Medical School—Director, Clinical Cardiology None None None None None None John H. Calhoon, Co-Chair University of Texas Health Science Center—Professor and Chair, CT Surgery Department None None None None None None Marc R. Moon Barnes-Jewish Hospital, Cardiothoracic Surgery, Washington Medical Center—Program Director, Professor of Surgery None None None None None None Carl L. Tommaso NorthShore University HealthSystem, Evanston Hospital—Interventional Cardiologist None None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees. According to the ACC, a person has a relevant relationship IF: (a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document ; or (b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document , or makes a competing drug or device addressed in the document; or (c) The person or a member of the person’s household, has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document . Appendix 2 Peer reviewer relationships with industry and other entities (relevant)—transcatheter therapies for mitral regurgitation: A professional society overview from the ACC, AATS, SCAI, and STS Peer reviewer Representation Employment Consultant Speaker’s bureau Ownership/ partnership/ principal Personal research Institutional, organizational, or other financial benefit Expert witness Steven R. Bailey Official Reviewer—SCAI University of Texas Medical Center—Professor of Medicine and Radiology None None • Biostar • Boston Scientific (DSMB) None None Deepak L. Bhatt Official Reviewer—ACC Task Force on Clinical Expert Consensus Documents VA Boston Healthcare System—Chief, Division of Cardiology None None None • Ethicon ∗ • Medtronic ∗ None None James A. Burke Content Reviewer—ACC Interventional Section Leadership Council Lehigh Valley Heart Specialists—Associate Chief of Cardiology None None None None None None Joaquin E. Cigarroa Content Reviewer—ACC Interventional Section Leadership Council Oregon Health & Science University, Knight Cardiovascular Institute—Clinical Professor of Medicine None None None None None None Marco A. Costa Content Reviewer—ACC Interventional Section Leadership Council University Hospitals Case Medical Center, Interventional Cardiovascular Center—Director • Abbott Vascular ∗ • Boston Scientific • Edwards Lifesciences • Medtronic • St. Jude Medical None None • St. Jude Medical • Abbott Vascular ∗ • Boston Scientific ∗ • Lutonics ∗ • Medtronic ∗ • St. Jude Medical None Abe DeAnda, Jr Official Reviewer—AATS New York University-Langone Medical Center—Associate Professor, Cardiothoracic Surgery None None None • Cook, Inc. † • Edwards Bioscience † • Ethicon † None None Linda D. Gillam Content Reviewer—ACC Cardiovascular Imaging Section Leadership Council Morristown Medical Center—Professor of Cardiology; Vice Chair, Cardiovascular Medicine None None None • Edwards Lifesciences † • Edwards Lifesciences † None Ziyad M. Hijazi Official Reviewer—SCAI Rush University Medical Center—Professor of Pediatrics and Internal Medicine; Rush Center for Congenital and Structural Heart Disease—Director • Occlutech ∗ None • Colibri Heart Valve † None None None David R. Holmes, Jr Official Reviewer—ACC BOT and Content Reviewer—NCDR TVT Registry Steering Committee Mayo Clinic—Consultant, Cardiovascular Diseases None None None None • Atritech † None Saibal Kar Content Reviewer—ACC Interventional Section Leadership Council Cedars-Sinai Medical Center, Division of Cardiology • Abbott Vascular ∗ • AGA Medical • Medtronic None • Abbott Vascular ∗ • Biosensor International ∗ • Boston Scientific ∗ • St. Jude Medical ∗ None None Michael J. Mack Content Reviewer—NCDR TVT Registry Steering Committee The Heart Hospital Baylor Plano—Director None None None • Edwards Lifesciences † None None Patrick M. McCarthy Official Reviewer—STS Northwestern University Feinberg School of Medicine—Surgical Director • Abbott Vascular ∗ • Direct Flow • Edwards Lifesciences ∗ None • Edwards Lifesciences ∗ • MiCardia None None None James B. McClurken Content Reviewer—ACC Surgeons Section Leadership Council Doylestown Hospital—Director of Thoracic Surgery, R A Reif Heart Institute; Temple University Hospital—Professor of Surgery (Cardiothoracic) Emeritus None None None None None None D. Craig Miller Official Reviewer—STS Stanford University Medical Center Cardiothoracic Surgery Clinic—Professor of Cardiovascular Surgery • Abbott Vascular • Edwards Lifesciences † • Medtronic ∗ • St. Jude Medical None None • Edwards Lifesciences † None None Hani K. Najm Content Reviewer—ACC Surgeons Section Leadership Council National Guard Health Affairs—Deputy Chairman and Head, Cardiac Surgery None None None None None None Stephen R. Ramee Content Reviewer—ACC Interventional Section Leadership Council Ochsner Clinic Foundation—Director, Cardiac Catheterization None None • Access Closure ∗ • Boston Scientific ∗ • Abbott † • Boston Scientific † • Edwards Lifesciences † • Medtronic † None None Pasala S. Ravichandran Content Reviewer—ACC Surgeons Section Leadership Council Oregon Health & Science University—Associate Professor None None None None None None Vinod H. Thourani Official Reviewer—AATS Emory University • Edwards Lifesciences • Sorin • St. Jude Medical None • Apica Cardiovascular † • Maquet None None Edward R. Tuohy, IV Official Reviewer—ACC Board of Governors Cardiac Specialists—Interventional Cardiologist; Yale-New Haven Health System—Interventional Cardiologist None None None None None None James S. Tweddell Content Reviewer—ACC Adult Congenital and Pediatric Cardiology Section Leadership Council Children’s Hospital of Wisconsin—The S. Bert Litwin Chair, Cardiothoracic Surgery; Medical College of Wisconsin—Professor of Surgery and Pediatrics; Chair, Division of Cardiothoracic Surgery None None None None None None Robert Vincent Content Reviewer—ACC Adult Congenital and Pediatric Cardiology Section Leadership Council Emory University School of Medicine—Professor of Pediatrics; Children’s Healthcare of Atlanta—Director, Cardiac Catheterization Laboratories None None None None • St. Jude Medical † None This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. According to the ACC, a person has a relevant relationship IF: (a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or (b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or (c) The person or a member of the person's household, has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document. DSMB , Data Safety Monitoring Board; NCDR , National Cardiovascular Data Registry; TVT , transcatheter valve therapy. ∗ Significant relationship. † No financial benefit.
PY - 2014/3
Y1 - 2014/3
UR - http://www.scopus.com/inward/record.url?scp=84894162994&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894162994&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2013.12.002
DO - 10.1016/j.jtcvs.2013.12.002
M3 - Article
C2 - 24529172
AN - SCOPUS:84894162994
SN - 0022-5223
VL - 147
SP - 837
EP - 849
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 3
ER -